AR050255A1 - Composicion farmaceutica conteniendo fragmentos polipeptidicos de serralisinas - Google Patents
Composicion farmaceutica conteniendo fragmentos polipeptidicos de serralisinasInfo
- Publication number
- AR050255A1 AR050255A1 ARP050102834A ARP050102834A AR050255A1 AR 050255 A1 AR050255 A1 AR 050255A1 AR P050102834 A ARP050102834 A AR P050102834A AR P050102834 A ARP050102834 A AR P050102834A AR 050255 A1 AR050255 A1 AR 050255A1
- Authority
- AR
- Argentina
- Prior art keywords
- composition
- serralisine
- pharmaceutical composition
- composition containing
- prodigiosins
- Prior art date
Links
- 239000012634 fragment Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
- 230000001772 anti-angiogenic effect Effects 0.000 abstract 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 230000009925 apoptotic mechanism Effects 0.000 abstract 1
- 210000004900 c-terminal fragment Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000002889 endothelial cell Anatomy 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/265—Enterobacter (G)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente está relacionada con una composicion capaz de inhibir el crecimiento de células tumorales de diferentes orígenes histologicos y de células endoteliales activadas. Los componentes de dicha composicion son fragmentos polipéptidos de Serralisinas, correspondientes al fragmento C-terminal, a partir de la metionina interna de la secuencia hasta el final de la molécula, los cuales pueden combinarse entre ellos y opcionalmente con prodigiosinas que potencian el efecto anti-tumoral de la composicion. Las prodigiosinas en la composicion pueden estar a una concentracion de 0.1-100 nM. La accion anti-proliferativa de la composicion está mediada por mecanismos apoptoticos. Su administracion "in vivo" tiene efecto antitumoral, antiangiogénico y protector contra tumores malignos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20040147A CU23475A1 (es) | 2004-07-08 | 2004-07-08 | Composición farmacéutica conteniendo fragmentos polipeptídicos de serralisinas |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR050255A1 true AR050255A1 (es) | 2006-10-11 |
Family
ID=40259088
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050102834A AR050255A1 (es) | 2004-07-08 | 2005-07-08 | Composicion farmaceutica conteniendo fragmentos polipeptidicos de serralisinas |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8076297B2 (es) |
| EP (1) | EP1787653B1 (es) |
| JP (1) | JP4914350B2 (es) |
| KR (1) | KR101365056B1 (es) |
| AR (1) | AR050255A1 (es) |
| AU (1) | AU2005262159B2 (es) |
| BR (1) | BRPI0513136A (es) |
| CA (1) | CA2572984C (es) |
| CU (1) | CU23475A1 (es) |
| CY (1) | CY1114201T1 (es) |
| DK (1) | DK1787653T3 (es) |
| ES (1) | ES2389126T3 (es) |
| HR (1) | HRP20120682T1 (es) |
| MX (1) | MX2007000339A (es) |
| MY (1) | MY150858A (es) |
| PL (1) | PL1787653T3 (es) |
| PT (1) | PT1787653E (es) |
| RS (1) | RS52448B (es) |
| RU (1) | RU2396274C2 (es) |
| SI (1) | SI1787653T1 (es) |
| WO (1) | WO2006005268A2 (es) |
| ZA (1) | ZA200700178B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2378777T3 (es) * | 2004-11-23 | 2012-04-17 | Zymogenetics, Inc. | Purificación del factor XIII humano recombinante |
| JP5296051B2 (ja) | 2007-05-04 | 2013-09-25 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | Ｍｒコイル吸収の補正を伴うハイブリッドｍｒ／ｐｅｔ |
| CU23950B1 (es) * | 2011-03-21 | 2013-10-29 | Ct De Ingeniería Genética Y Biotecnología | Péptidos cíclicos con actividad antineoplásica y antiangiogénica |
| TWI746449B (zh) * | 2015-07-20 | 2021-11-21 | 美商Ａｉ治療公司 | 使用阿吡莫德治療癌症之方法 |
| CN109295041A (zh) * | 2018-10-10 | 2019-02-01 | 宁波希诺亚海洋生物科技有限公司 | 具有舍雷肽酶活性的多肽及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58134991A (ja) * | 1981-12-28 | 1983-08-11 | Takeda Chem Ind Ltd | セラチオペプチタ−ゼの安定化法 |
| JP2611206B2 (ja) * | 1985-11-15 | 1997-05-21 | 武田薬品工業株式会社 | 遺伝子およびその利用方法 |
| KR100252197B1 (ko) * | 1997-09-20 | 2000-04-15 | 박호군 | 세라시아 마르세센스 균주의 배양액으로 부터 분리한 면역억제제용 프로디지오신 |
| CA2328076C (en) * | 1998-04-15 | 2009-10-06 | Lexigen Pharmaceuticals Corporation | Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor |
| US20040185566A1 (en) * | 2003-03-19 | 2004-09-23 | Peter Salamone | Polypeptides toxic to nematodes and methods of use |
-
2004
- 2004-07-08 CU CU20040147A patent/CU23475A1/es unknown
-
2005
- 2005-07-05 SI SI200531578T patent/SI1787653T1/sl unknown
- 2005-07-05 RS RS20120391A patent/RS52448B/sr unknown
- 2005-07-05 US US11/631,880 patent/US8076297B2/en not_active Expired - Fee Related
- 2005-07-05 DK DK05762122.9T patent/DK1787653T3/da active
- 2005-07-05 CA CA2572984A patent/CA2572984C/en not_active Expired - Fee Related
- 2005-07-05 AU AU2005262159A patent/AU2005262159B2/en not_active Ceased
- 2005-07-05 BR BRPI0513136-7A patent/BRPI0513136A/pt not_active Application Discontinuation
- 2005-07-05 KR KR1020077002589A patent/KR101365056B1/ko not_active Expired - Fee Related
- 2005-07-05 RU RU2007104776/13A patent/RU2396274C2/ru not_active IP Right Cessation
- 2005-07-05 JP JP2007519599A patent/JP4914350B2/ja not_active Expired - Fee Related
- 2005-07-05 PL PL05762122T patent/PL1787653T3/pl unknown
- 2005-07-05 HR HRP20120682TT patent/HRP20120682T1/hr unknown
- 2005-07-05 WO PCT/CU2005/000003 patent/WO2006005268A2/es not_active Ceased
- 2005-07-05 PT PT05762122T patent/PT1787653E/pt unknown
- 2005-07-05 ES ES05762122T patent/ES2389126T3/es not_active Expired - Lifetime
- 2005-07-05 MX MX2007000339A patent/MX2007000339A/es active IP Right Grant
- 2005-07-05 EP EP05762122A patent/EP1787653B1/en not_active Expired - Lifetime
- 2005-07-07 MY MYPI20053102 patent/MY150858A/en unknown
- 2005-07-08 AR ARP050102834A patent/AR050255A1/es active IP Right Grant
-
2007
- 2007-01-05 ZA ZA200700178A patent/ZA200700178B/xx unknown
-
2012
- 2012-09-05 CY CY20121100800T patent/CY1114201T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2007000339A (es) | 2007-03-12 |
| ZA200700178B (en) | 2008-06-25 |
| US8076297B2 (en) | 2011-12-13 |
| WO2006005268A2 (es) | 2006-01-19 |
| US20110218138A1 (en) | 2011-09-08 |
| RU2396274C2 (ru) | 2010-08-10 |
| WO2006005268A3 (es) | 2006-03-09 |
| RU2007104776A (ru) | 2008-08-20 |
| CY1114201T1 (el) | 2016-08-31 |
| KR20070042542A (ko) | 2007-04-23 |
| KR101365056B1 (ko) | 2014-02-21 |
| MY150858A (en) | 2014-03-14 |
| SI1787653T1 (sl) | 2012-10-30 |
| JP2008505129A (ja) | 2008-02-21 |
| AU2005262159A1 (en) | 2006-01-19 |
| EP1787653B1 (en) | 2012-06-06 |
| DK1787653T3 (da) | 2012-09-17 |
| PL1787653T3 (pl) | 2012-11-30 |
| CA2572984C (en) | 2014-12-09 |
| JP4914350B2 (ja) | 2012-04-11 |
| RS52448B (sr) | 2013-02-28 |
| EP1787653A2 (en) | 2007-05-23 |
| PT1787653E (pt) | 2012-09-06 |
| HRP20120682T1 (hr) | 2012-09-30 |
| CU23475A1 (es) | 2009-12-17 |
| ES2389126T3 (es) | 2012-10-23 |
| AU2005262159B2 (en) | 2011-08-18 |
| CA2572984A1 (en) | 2006-01-19 |
| BRPI0513136A (pt) | 2008-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR060306A1 (es) | Terapia de combinacion de anticuerpos contra ctla4 | |
| ATE535252T1 (de) | Peptid-konjugat-zusammensetzungen und -verfahren zur prävention und behandlung von alzheimer- krankheit | |
| BR0316050A (pt) | Métodos de tratar, controlar ou prevenir um câncer especìfico e doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com terapia de radiação, terapia hormonal, terapia biológica, ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit | |
| MX383644B (es) | Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion. | |
| CY1111065T1 (el) | Φαρμακευτικη συνθεση που περιεχει μια ωμεγα-καρβοξυαρυλ υποκατεστημενη διφαινυλ ουρια για τη θεραπευτικη αντιμετωπιση του καρκινου | |
| CR10244A (es) | Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano | |
| MX2010002716A (es) | Uso de slit, nefrina, efrina o semaforina para el tratamiento de enfermedades de cartilago. | |
| EA200800268A1 (ru) | КОМБИНИРОВАННАЯ ТЕРАПИЯ АНТИТЕЛОМ ПРОТИВ CTLA-4 И СОДЕРЖАЩИМ CpG-МОТИВ СИНТЕТИЧЕСКИМ ОЛИГОДЕЗОКСИНУКЛЕОТИДОМ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ | |
| AR024074A1 (es) | FRAGMENTO ABETA UNIDO A UN PÉPTIDO PORTADOR PARA PREVENIR O TRATAR ENFERMEDADES ASOCIADAS CON DEPoSITOS AMILOIDES DE ABETA, COMPOSICIONES FARMACÉUTICAS QUE LO CONTIENEN, Y SU USO EN LA PREPARACION DE MEDICAMENTOS. | |
| AR053651A1 (es) | Tratamiento combinado de anticuerpo antictla4 r inhibidor de aromatasa para el cancer de mama | |
| CL2008001813A1 (es) | Compuestos derivados de quinolin-3-carbonitrilo sustituidos con piperazina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis, inflamacion, cancer entre otras (div. sol. 266-04). | |
| AR080891A1 (es) | Proteina de fusion robo 1-fc y su utilizacion en el tratamiento de tumores | |
| PT1691824E (pt) | Proteínas pertencentes à família bcl-2 e seus fragmentos e sua utilização em doentes de cancro | |
| BRPI0508700A (pt) | uso de sns-595, composição farmacêutica, e, pó liofilizado | |
| NO20072543L (no) | Anti-cancer-behandling | |
| BR112014024358A2 (pt) | uso de iduronate-2-sulfatase por via subcutânea e kit | |
| AR056586A1 (es) | Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras | |
| MX337358B (es) | Conjugados de disorazoles y sus derivados con moleculas de union con celulas, nuevos derivados de disorazol, procesos de fabricacion y usos de los mismos. | |
| AR050255A1 (es) | Composicion farmaceutica conteniendo fragmentos polipeptidicos de serralisinas | |
| WO2010023195A3 (en) | Compositions and methods for treating cancer | |
| AR115883A1 (es) | Composición farmacéutica para el tratamiento de la adicción a sustancias psicoactivas y/o para la prevención de las recaídas a dicha adicción | |
| ATE552271T1 (de) | Antitumorarzneimittel, medikament, zusammensetzung und anwendung davon | |
| KR960700734A (ko) | 사람 암에 대한 시스플래틴/타목시펜 배합 치료(Combination cisplatin/tamoxifen therapy for human cancers) | |
| GB0507598D0 (en) | Composition | |
| ATE484290T1 (de) | Peptid mit antitumoraler wirkung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |